Angiogenesis and multiple myeloma: Exploring prognostic potential of adrenomedullin

Abstract Background Adrenomedullin (AM) is a multifunctional peptide which under basal conditions mainly regulates vasodilation and maintains vascular integrity but is also implicated in the pathogenesis of several malignancies, including multiple myeloma (MM). It has been shown that adrenomedullin...

Full description

Saved in:
Bibliographic Details
Main Authors: Angelos Giannakoulas, Panagiotis Stoikos, Evangelia Kouvata, Katerina M. Kontouli, Georgios Fotiadis, Georgia Stefani, Grigorios D. Amoutzias, George Vassilopoulos, Nikolaos Giannakoulas
Format: Article
Language:English
Published: Wiley 2024-09-01
Series:Cancer Medicine
Subjects:
Online Access:https://doi.org/10.1002/cam4.70250
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Adrenomedullin (AM) is a multifunctional peptide which under basal conditions mainly regulates vasodilation and maintains vascular integrity but is also implicated in the pathogenesis of several malignancies, including multiple myeloma (MM). It has been shown that adrenomedullin is expressed by human myeloma cell lines and that it enhances MM‐driven angiogenesis. However, the clinical impact of AM remains unknown. Materials and Methods On that basis, we enrolled 32 newly diagnosed multiple myeloma patients (NDMM) and studied the potential of AM as a prognostic biomarker. Results We report that elevated levels of AM trend with suboptimal treatment response and inferior survival of NDMM patients.
ISSN:2045-7634